RAS–MAPK–MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nature

• Publication date

  2013-05-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature12204PMID 23719381PMCID PMC4020154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

  2012cited by this paper
• Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

  2012cited by this paper
• MAP kinase pathways.

  2012cited by this paper
• Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways.

  2011cited by this paper
• Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3ε haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration

  2011cited by this paper
• Ageing, neurodegeneration and Parkinson's disease.

  2010influential reference
• Acetylation targets mutant huntingtin to autophagosomes for degradation.

  2009cited by this paper
• Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms

  2009cited by this paper
• Phosphorylation of ATXN1 at Ser776 in the cerebellum

  2009cited by this paper
• Pathogenic Mechanisms of a Polyglutamine-mediated Neurodegenerative Disease, Spinocerebellar Ataxia Type 1*

  2009cited by this paper
• Animal models of Alzheimer's disease and frontotemporal dementia

  2008cited by this paper
• The prion organotypic slice culture assay—POSCA

  2008cited by this paper
• Polyglutamine neurodegeneration: protein misfolding revisited.

  2008cited by this paper
• Translating insights from the cancer genome into clinical practice

  2008cited by this paper
• Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1

  2008cited by this paper
• Distinct pathways for the involvement of WNK4 in the signaling of hypertonicity and EGF

  2008cited by this paper
• Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

  2007cited by this paper
• Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes

  2007cited by this paper
• dAtaxin-2 Mediates Expanded Ataxin-1-Induced Neurodegeneration in a Drosophila Model of SCA1

  2007cited by this paper
• APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

  2006cited by this paper
• Critical nodes in signalling pathways: insights into insulin action

  2006cited by this paper
• RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

  2005cited by this paper
• ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions

  2004cited by this paper
• Protein Kinase Inhibitors: Insights into Drug Design from Structure

  2004cited by this paper
• RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia

  2004cited by this paper
• Recovery from Polyglutamine-Induced Neurodegeneration in Conditional SCA1 Transgenic Mice

  2004cited by this paper
• Molecular clearance of ataxin‐3 is regulated by a mammalian E4

  2004cited by this paper
• Protein aggregation and neurodegenerative disease

  2004cited by this paper
• α-synuclein locus duplication as a cause of familial Parkinson's disease

  2004cited by this paper
• Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

  2004cited by this paper
• α-Synuclein Locus Triplication Causes Parkinson's Disease

  2003cited by this paper
• Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice.

  2003cited by this paper
• alpha-Synuclein locus triplication causes Parkinson's disease.

  2003cited by this paper
• Treatment of Alzheimer's disease: current status and new perspectives.

  2003cited by this paper
• A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration.

  2002cited by this paper
• Toxic Proteins in Neurodegenerative Disease

  2002cited by this paper
• MSK1 and MSK2 Are Required for the Mitogen- and Stress-Induced Phosphorylation of CREB and ATF1 in Fibroblasts

  2002cited by this paper
• Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway

  2001cited by this paper
• MSK1 is required for CREB phosphorylation in response to mitogens in mouse embryonic stem cells

  2000cited by this paper
• The discovery of potent cRaf1 kinase inhibitors.

  2000cited by this paper
• Repeat instability and motor incoordination in mice with a targeted expanded CAG repeat in the Sca1 locus.

  2000cited by this paper
• Glutamine repeats and neurodegeneration.

  2000cited by this paper
• Identification of genes that modify ataxin-1-induced neurodegeneration

  2000cited by this paper
• Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.

  2000cited by this paper
• MAP kinase pathways.

  1999cited by this paper
• Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.

  1999cited by this paper
• Mitogen‐ and stress‐activated protein kinase‐1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB

  1998cited by this paper
• Insulin signal transduction through protein kinase cascades

  1998cited by this paper
• SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat.

  1995cited by this paper
• Expression analysis of the ataxin–1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals

  1995cited by this paper
• Estimated prevalence of Alzheimer's disease in the United States.

  1990influential reference
• Success and problems of long-term levodopa therapy in Parkinson's disease.

  1977cited by this paper
• Letter: Hepanosticon in screening for HBsAg.

  1975cited by this paper

• Integrative transcriptome-wide association analyses reveal PRKCG-linked GABAergic dysfunction in Fragile X-associated tremor/ataxia syndrome

  2026cites this paper
• Repurposing of natural products for spinocerebellar ataxia type 3 using integrated network pharmacology and in silico approaches

  2026cites this paper
• Modulation of Karyopherin Levels Attenuates Mutant Ataxin-1-Induced Neurodegeneration

  2025cites this paper
• Translational Relevance of SCA1 Models for the Development of Therapies for Spinocerebellar Ataxia Type 1

  2025cites this paper
• Molecular hallmarks of neurodegeneration in polyglutamine spinocerebellar ataxias

  2025cites this paper
• Spinocerebellar Ataxia Type 1 (SCA1) Cell Models Display Widespread Mitochondrial and Extra-Nuclear Alterations

  2025influential citation
• MEK1/2 inhibitors suppress pathological α-synuclein and neurotoxicity in cell models and a humanized mouse model of Parkinson's disease.

  2025cites this paper
• Involvement of mitogen- and stress-activated protein kinase 1 in BMP-6–induced chondrocyte differentiation

  2024cites this paper
• A fluorescence‐based sensor for calibrated measurement of protein kinase stability in live cells

  2024cites this paper
• Novel trifluoromethyl ketone derivatives as oral cPLA2/COX-2 dual inhibitors for resolution of inflammation in rheumatoid arthritis.

  2024cites this paper
• Hereditary Ataxias: From Bench to Clinic, Where Do We Stand?

  2024cites this paper
• On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3

  2023influential citation
• Necroptosis in CNS diseases: Focus on astrocytes

  2023cites this paper
• A Fluorescence-Based Sensor for Calibrated Measurement of Protein Kinase Stability in Live Cells

  2023cites this paper
• Drosophila melanogaster as a model to study autophagy in neurodegenerative diseases induced by proteinopathies

  2023cites this paper
• Functional variants identify sex-specific genes and pathways in Alzheimer’s Disease

  2023cites this paper
• Mitogen- and stress-activated protein kinase (MSK1/2) regulated gene expression in normal and disease states.

  2023cites this paper
• Cross-species genetic screens identify transglutaminase 5 as a regulator of polyglutamine-expanded ataxin-1

  2022influential citation
• Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1

  2022cites this paper
• Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2

  2022cites this paper
• Identifying Disease Signatures in the Spinocerebellar Ataxia Type 1 Mouse Cortex

  2022cites this paper
• Identification of risk genes for Alzheimer’s disease by gene embedding

  2022cites this paper
• Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets

  2022cites this paper
• MAPK-Activated Protein Kinases: Servant or Partner?

  2022cites this paper
• Understanding and drugging RAS: 40 years to break the tip of the iceberg

  2022cites this paper
• PAK4 suppresses motor neuron degeneration in hSOD1G93A‐linked amyotrophic lateral sclerosis cell and rat models

  2021cites this paper
• Modulation of ATXN1 S776 phosphorylation reveals the importance of allele-specific targeting in SCA1

  2021cites this paper
• Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2

  2021cites this paper
• Longitudinal single-cell transcriptional dynamics throughout neurodegeneration in SCA1

  2021cites this paper
• Intercellular Propagation and Aggregate Seeding of Mutant Ataxin-1

  2021cites this paper
• Decoding the role of coiled-coil motifs in human prion-like proteins

  2021cites this paper
• A Structural Study of the Cytoplasmic Chaperone Effect of 14-3-3 Proteins on Ataxin-1

  2021cites this paper
• Genetic Modeling of the Neurodegenerative Disease Spinocerebellar Ataxia Type 1 in Zebrafish

  2021cites this paper
• DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases

  2021cites this paper
• RACK1 modulates polyglutamine-induced neurodegeneration by promoting ERK degradation in Drosophila

  2021cites this paper
• Dissecting the complexity of CNV pathogenicity: insights from Drosophila and zebrafish models.

  2021cites this paper
• Dual targeting of brain region‐specific kinases potentiates neurological rescue in Spinocerebellar ataxia type 1

  2021influential citation
• Pathogenic mechanisms underlying spinocerebellar ataxia type 1

  2020cites this paper
• PAK4 Suppresses Motor Neuron Degeneration in hSOD1G93A -Linked ALS Cell and Rat Models

  2020influential citation
• Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS

  2020cites this paper
• Dosage-sensitive genes in autism spectrum disorders: From neurobiology to therapy.

  2020cites this paper
• Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment

  2020cites this paper
• miR760 regulates ATXN1 levels via interaction with its 5′ untranslated region

  2020cites this paper
• Attenuation of epigenetic regulator SMARCA4 and ERK‐ETS signaling suppresses aging‐related dopaminergic degeneration

  2020cites this paper
• 5'UTR-mediated regulation of Ataxin-1 expression.

  2020cites this paper
• Combination of whole exome sequencing and animal modeling identifies TMPRSS9 as a candidate gene for autism spectrum disorder.

  2020cites this paper
• Acetylation of cedrelone increases its cytotoxic activity and reverts the malignant phenotype of breast cancer cells in 3D culture.

  2019cites this paper
• Unraveling Novel Mechanisms of Neurodegeneration Through a Large-Scale Forward Genetic Screen in Drosophila

  2019cites this paper
• A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability

  2019cites this paper
• Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease.

  2019cites this paper
• Beta-binomial modeling of CRISPR pooled screen data identifies target genes with greater sensitivity and fewer false negatives

  2019cites this paper
• Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials

  2019cites this paper
• Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide

  2019cites this paper
• Recent Advances in the Treatment of Cerebellar Disorders

  2019cites this paper
• Attenuation of epigenetic regulator SMARCA4 and ERK-ETS signaling suppresses aging-related dopaminergic degeneration

  2019cites this paper
• Understanding Neurodegeneration and Neuroprotection Through Genetic Screens in Drosophila

  2019cites this paper
• Combinatorial Impact of α-Synuclein Post-Translational Modifications in Yeast

  2019cites this paper
• Spinocerebellar Ataxia Type 1: Molecular Mechanisms of Neurodegeneration and Preclinical Studies.

  2018cites this paper
• The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology.

  2018cites this paper
• Spinocerebellar ataxias: prospects and challenges for therapy development

  2018cites this paper
• Roles of Post-translational Modifications in Spinocerebellar Ataxias

  2018cites this paper
• A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach

  2018cites this paper
• Molecular mechanisms of the juvenile form of Batten disease: important role of MAPK signaling pathways (ERK1/ERK2, JNK and p38) in pathogenesis of the malady

  2018cites this paper
• Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.

  2018cites this paper
• MTSS1/Src family kinase dysregulation underlies multiple inherited ataxias

  2018cites this paper
• ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism.

  2018cites this paper
• Paradigm for disease deconvolution in rare neurodegenerative disorders in Indian population: insights from studies in cerebellar ataxias

  2018cites this paper
• Repeat Expansion Disease Models.

  2018cites this paper
• Why do so many genetic insults lead to Purkinje Cell degeneration and spinocerebellar ataxia?

  2018cites this paper
• PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in spinocerebellar ataxia type 1

  2018cites this paper
• The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer

  2018cites this paper
• Targeting Gpr52 lowers mutant HTT levels and rescues Huntington’s disease-associated phenotypes

  2018influential citation
• Control of CNS Functions by RNA-Binding Proteins in Neurological Diseases

  2018cites this paper
• Novel Modifiers of Aβ42 Toxicity in Drosophila

  2018influential citation
• Elucidating regulators and biomarkers of synaptic stability during neurodegeneration

  2018cites this paper
• The ataxin-1 interactome reveals direct connection with multiple disrupted nuclear transport pathways

  2018cites this paper
• Reduction of protein kinase A-mediated phosphorylation of ATXN1-S776 in Purkinje cells delays onset of Ataxia in a SCA1 mouse model.

  2018influential citation
• Laminin signals initiate the reciprocal loop that informs breast-specific gene expression and homeostasis by activating NO, p53 and microRNAs

  2017cites this paper
• Genetic Screens in Neurodegeneration

  2017cites this paper
• Neurotoxicity Pathways in Drosophila Models of the Polyglutamine Disorders.

  2017cites this paper
• Disruption of the ATXN1–CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans

  2017cites this paper
• Short-term succinic acid treatment mitigates cerebellar mitochondrial OXPHOS dysfunction, neurodegeneration and ataxia in a Purkinje-specific spinocerebellar ataxia type 1 (SCA1) mouse model

  2017cites this paper
• Spinocerebellar ataxia: miRNAs expose biological pathways underlying pervasive Purkinje cell degeneration.

  2017cites this paper
• Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models

  2017cites this paper
• Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases

  2017cites this paper
• Disruption of the ATXN1–CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans

  2017cites this paper
• WNK Kinases in Development and Disease.

  2017influential citation
• Ataxin-1 is involved in tumorigenesis of cervical cancer cells via the EGFR–RAS–MAPK signaling pathway

  2017cites this paper
• A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking

  2017cites this paper
• Polyglutamine expansion diseases: More than simple repeats.

  2017cites this paper
• Metal Homeostasis Regulators Suppress FRDA Phenotypes in a Drosophila Model of the Disease

  2016cites this paper
• Neurodegeneration: From cellular concepts to clinical applications

  2016cites this paper
• Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models.

  2016cites this paper
• BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1.

  2016cites this paper
• Emerging Roles of the Mitogen and Stress Activated Kinases MSK1 and MSK2

  2016cites this paper
• Huntington’s Disease Studies at the Interface of Chemistry, Physics, and Biology

  2016cites this paper
• TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau

  2016influential citation
• Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model.

  2016cites this paper
• Polyglutamine length-dependent toxicity from α1ACT in Drosophila models of spinocerebellar ataxia type 6

  2016cites this paper
• Drosophila Mitf regulates the V-ATPase and the lysosomal-autophagic pathway

  2016cites this paper